Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology

Melissa H. Bloodworth, Vanderbilt University
Mark Rusznak, Vanderbilt University
Connor C. Pfister, Vanderbilt University
Jian Zhang, Vanderbilt University
Lisa Bastarache, Vanderbilt University
Sandra Alvarez Calvillo, Vanderbilt University
James D. Chappell, Vanderbilt University
Kelli L. Boyd, Vanderbilt University
Shinji Toki, Vanderbilt University
Dawn C. Newcomb, Vanderbilt University

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Allergy and Clinical Immunology

Volume: Volume 142, Number 2

Publisher: Elsevier | 2018-08-01, Pages 683-687

Type of Work: Article | Post-print: After Peer Review

Publisher DOI: 10.1016/j.jaci.2018.01.053

Permanent URL: https://pid.emory.edu/ark:/25593/v2pn

Final published version: http://dx.doi.org/10.1016/j.jaci.2018.01.053

Copyright information:

© 2018 American Academy of Allergy, Asthma & Immunology

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Glucagon-like peptide-1 receptor signaling attenuates RSV-induced type 2 responses and immunopathology

Melissa H. Bloodworth, Ph.D.a, Mark Rusznakb, Connor C. Pfisterb, Jian Zhang, M.S.b, Lisa Bastarache, Ph.D.c, Sandra Alvarez Calvillo, B.S.d, James D. Chappell, M.D., Ph.D.d, Kelli L. Boyd, D.V.M., Ph.D.a, Shinji Toki, Ph.D.b, Dawn C. Newcomb, Ph.D.a,b, Matthew T. Stier, B.S.a, Weisong Zhou, Ph.D.b, Kasia Goleniewska, M.S.b, Martin L. Moore, Ph.D.e, Tina V. Hartert, M.D., M.P.H.b, Kevin D. Niswender, M.D., Ph.D.f,*, and R. Stokes Peebles Jr., M.D.a,b,*

a Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA
b Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
c Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA
d Division of Infectious Disease, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
e Division of Infectious Disease, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
f Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

Capsule Summary

GLP-1R signaling, an emerging anti-inflammatory therapeutic target, attenuated type 2-associated immunopathology in mice infected with a strain of RSV that was isolated from a hospitalized infant with severe lower respiratory tract infection and bronchiolitis.

Keywords

glucagon-like peptide-1 (GLP-1); respiratory syncytial virus (RSV); group 2 innate lymphoid cells (ILC2); IL-13; IL-33; type 2 immunity (Th2); phenome-wide association study (PheWAS)
Glucagon-like peptide-1 receptor (GLP-1R) agonists, which potentiate insulin and suppress glucagon secretion, are a well-accepted and safe treatment for Type II diabetes.\(^1\) Although GLP-1R agonists are currently used for their ability to potentiate insulin and suppress glucagon secretion, recent evidence suggests that GLP-1R signaling also has anti-inflammatory effects.\(^2\)–\(^4\) Severe RSV-associated illness is in part caused by IL-13 production, which mediates the mucus production that directly contributes to airway obstruction and respiratory failure.\(^5\) We hypothesized that GLP-1R signaling inhibits IL-13-mediated immunopathology of RSV 12/12-6, a strain of RSV that was isolated from a hospitalized infant with severe lower respiratory tract infection and bronchiolitis.

Eight week old mice were infected with $9 \times 10^5$ PFU of RSV. RSV 12/12-6 induced significant lung IL-13 and airway mucus, mimicking what is seen in patients with severe infection (Fig E1). We administered GLP-1R agonist or vehicle (0.1% BSA in PBS) twice daily beginning 2 days prior to RSV infection until all endpoints (Fig E2). GLP-1R agonist treatment significantly decreased lung IL-13 protein expression compared to vehicle treatment in RSV-infected mice (Fig 1, A). We identified the cellular sources of IL-13 that GLP-1R signaling was inhibiting. GLP-1R agonist treatment in RSV-infected mice significantly decreased the total number of cells in the lung, the total number of group 2 innate lymphoid cells (ILC2), and the percentage of ILC that were IL-13\(^+\) compared to RSV-infected vehicle-treated mice (Fig E3A, Fig E4A\&F & Fig 1, B\&E). There was significantly decreased MFI of IL-13 and CD127 on the ILC2 of RSV-infected GLP-1R agonist-treated mice compared to RSV-infected vehicle-treated mice, indicating decreased IL-13 production and CD127 expression on a per ILC2 basis with GLP-1R agonist treatment (Fig E4B–E).

GLP-1R agonist treatment in RSV-infected mice significantly decreased the numbers of CD4\(^+\) T cells and basophils, as well as IL-13\(^+\) Th2 cells and basophils compared to RSV-infected vehicle-treated mice (Fig E3B–C, Fig E4G–H & Fig 1, C–D).

Moreover, there were significant decreases in methacholine-induced airway responsiveness and mucus severity scores in RSV-infected GLP-1R agonist-treated mice compared to RSV-infected vehicle-treated mice (Fig 1, F–H). RSV-infected GLP-1R agonist-treated mice had significantly decreased numbers of total bronchoalveolar lavage (BAL) cells and lymphocytes compared to RSV-infected vehicle-treated mice (Fig 1, I). Administration of the GLP-1R agonist beginning 2 days after RSV infection also significantly decreased lung IL-13 and there was a trend towards decreased airway mucus (Fig E5). Collectively, these data demonstrate that GLP-1R signaling attenuates IL-13-mediated immunopathology during RSV infection.

IL-33 activates type 2 cytokine-producing immune cells including ILC2, Th2, and basophils. We used Il33\(^{Citrine^+}\) reporter mice to examine the effect of GLP-1R signaling on IL-33 expression on a per epithelial cell basis. GLP-1R agonist treatment in RSV-infected mice significantly decreased the total number of cells in the lung, the total number of IL-33-expressing epithelial cells, and the percentage of epithelial cells that were IL-33\(^+\) compared to RSV-infected vehicle-treated mice (Fig E6A–B & Fig 2, A). There was significantly decreased MFI of IL-33 in the epithelial cells of RSV-infected GLP-1R agonist-treated mice.

\(J\) Allergy Clin Immunol. Author manuscript; available in PMC 2019 August 01.
compared to RSV-infected vehicle-treated mice, indicating decreased IL-33 expression on a per epithelial cell basis with GLP-1R agonist treatment (Fig 2, B–C). RSV-infected GLP-1R agonist-treated mice had significantly decreased lung IL-33 protein expression compared to RSV-infected vehicle-treated mice (Fig 2, D). These data indicate that GLP-1R agonist treatment inhibits the expression of IL-33 by epithelial cells during RSV infection.

To determine whether GLP-1R agonist treatment had a deleterious effect on viral-associated disease severity parameters, we evaluated viral load, an indicator of RSV disease severity. There were no significant differences in the viral load between RSV-infected GLP-1R agonist and vehicle-treated mice (Fig 2, E). Consistent with these data, we did not observe any significant differences in lung interferon-γ (IFN-γ) expression or IFN-γ+ Th1 and natural killer (NK) cells between RSV-infected GLP-1R agonist and vehicle-treated mice 6 days post-infection (Fig E4B& D, Fig 2, F & Fig E7A–B). Further, there were no significant differences in lung IFN-α, IFN-β, or IL-27 protein expression between RSV-infected GLP-1R agonist and vehicle-treated mice (Fig E7C–E). We also found that there were no statistically significant changes in plasma glucose or insulin levels with GLP-1R treatment compared to vehicle (Fig E7F & G).

To determine whether GLP-1R agonist treatment during primary infection has an impact on the immune response to a later secondary infection, we infected mice with RSV a second time following primary RSV infection (Fig E8). GLP-1R agonist treatment during primary infection significantly decreased the number of RSV-induced total BAL cells and lymphocytes compared to vehicle treatment after secondary infection (Fig E9A). The mice treated with GLP-1R agonist during primary infection did not exhibit altered lung IFN-γ expression nor RSV F-protein-specific antibody responses compared to vehicle-treated mice during secondary RSV infection (Fig E9B–E). These data demonstrate that GLP-1R agonist treatment does not exacerbate disease or impede anti-viral responses.

We next sought to identify associations between GLP-1 signaling and human RSV disease. The phenome-wide association study (PheWAS) is a new, validated reverse genetics approach that associates genetic variants of interest with phenotypes by linking a database of de-identified genotyping to a broad range of electronic medical record (EMR)-derived clinical phenotypes. The EMR phenotypes are derived from cluster of common International Classification of Diseases, Ninth Revision, codes. The loss-of-function rs7578597 variant of THADA, encoding thyroid adenoma-associated protein, is associated with lower beta-cell response to GLP-1. A PheWAS on the single nucleotide polymorphism (SNP) rs7578597 (missense, T1187A) and 1,000 phenotypes from the Vanderbilt BioVU biobank of 29,713 individuals of European ancestry (EA) revealed a highly significant association of rs7578597 with acute bronchitis and bronchiolitis (OR = 1.24, P = 6.3 × 10⁻³; Fig 2, G and Table E1).

This study is the first investigation of GLP-1R signaling during viral infection. We show that administration of a GLP-1R agonist attenuates type 2-associated immunopathology during RSV infection. This is also the first report of an FDA-approved pharmacologic agent inhibiting lung IL-33 protein expression, and this finding has significant implications as it may provide an alternative to biologic therapies such as monoclonal antibodies or receptor.
antagonists that target IL-33-mediated diseases. Together, these data highlight a novel potential therapeutic for RSV infection, a disease for which there currently is no treatment after infection has occurred.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding:

R01 AI 124456 – R. S. P.
U19 AI 095227 – R. S. P.
R01 AI 111820 – R. S. P.
2I01BX000624 – R. S. P.
T32 GM07347 – Vanderbilt MSTP
F30 AI118376– M. H. B.

We thank Anne Hotard for isolation of RSV clinical isolate 12/2-6; Janey Wang for managing the rs7578597 PheWAS study; John T. Bates and James E. Crowe Jr. for RSV F protein; Kevin P. Weller, David K. Flaherty, and Brittany Matlock in the VUMC Flow Cytometry Shared Resource for technical assistance; and Andrew N. J. McKenzie for Il33Citrine/Citrine mice. The VUMC Flow Cytometry Shared Resource is supported by the Vanderbilt Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive Disease Research Center (DK058404). The PheWAS study was supported by the National Center for Research Resources, Grant UL1 RR024975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Abbreviations used

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILC2</td>
<td>group 2 innate lymphoid cells</td>
</tr>
<tr>
<td>RSV</td>
<td>respiratory syncytial virus</td>
</tr>
<tr>
<td>Th2</td>
<td>T helper 2</td>
</tr>
<tr>
<td>GLP-1</td>
<td>glucagon-like peptide-1</td>
</tr>
<tr>
<td>WT</td>
<td>wild type</td>
</tr>
<tr>
<td>MFI</td>
<td>mean fluorescence intensity</td>
</tr>
<tr>
<td>PFU</td>
<td>plaque forming unit</td>
</tr>
<tr>
<td>PheWAS</td>
<td>phenome-wide association study</td>
</tr>
</tbody>
</table>

References


Figure 1. GLP-1R agonist decreases RSV-induced type 2 responses and immunopathology

(A) ELISA for IL-13 in whole lung homogenate (right lung only). (B) Total number of IL-13+ ILC2, (C) Th2 cells, and (D) basophils. (E) Representative IL-13 expression measured by flow cytometry in ILC2. (F) Representative PAS-stained section of mucus-containing airways in the lungs (40x magnification); arrowhead denotes intraluminal mucus strand. (G) Quantification of airway mucus from the experiment in A. (H) Airway responsiveness and (I) BAL cell counts. Data plotted as mean ± SEM. n = 3–6 mice per group representative of 3 (A) or 2 (B–G & I) independent experiments. n = 6–12 mice per group combined from 2 independent experiments (H). *p < 0.05, **p < 0.01, ***p < 0.001 by one-way (B & E–H) or two-way (C–D) ANOVA. BL = baseline.
Figure 2. GLP-1R signaling decreases IL-33, does not increase viral titer or decrease IFN-γ production, and associates with acute bronchiolitis in humans

(A) Total number of IL-33+ epithelial cells, (B) MFI of IL-33 expression in epithelial cells, (C) representative IL-33 expression measured by flow cytometry in epithelial cells, and (D) ELISA for IL-33 in whole lung homogenate (left lung only). (E) Lung mRNA RSV M protein expression normalized to GAPDH. (F) ELISA for IFN-γ in whole lung homogenate (right lung only). (G) Phenome-wide association study (PheWAS) plot for THADA rs7578597 using logistic regression assuming an additive genetic model adjusted for age, sex, study site, and the first 3 principal components. rs7578597 associated with acute bronchiolitis (OR = 1.24, P = 6.3 × 10^{-3}). Data plotted as mean + SEM. n = 3–6 mice per group representative of 2 independent experiments (A–F). *p < 0.05, **p < 0.01, ***p < 0.001 by one-way (A–B, D, & F) or two-way (E) ANOVA. NS = not significant.